Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)-Reference-Cited by-同舟云学术

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

Published:2019-02-28 Issue:3 Volume:25 Page:373-381
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Curry Nicola¹^ORCID,Albayrak Canan²,Escobar Miguel³^ORCID,Andre Holme Pål⁴,Kearney Susan⁵,Klamroth Robert⁶,Misgav Mudi⁷,Négrier Claude⁸,Wheeler Allison⁹,Santagostino Elena¹⁰,Shima Midori¹¹,Landorph Andrea¹²,Tønder Sidsel Marie¹²,Lentz Steven R.¹³^ORCID

Affiliation:

1. Oxford Haemophilia and Thrombosis Centre and Oxford NIHR BRC Churchill Hospital Oxford UK

2. Department of Pediatric Hematology and Oncology, Faculty of Medicine Ondokuz Mayis University Samsun Turkey

3. McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center University of Texas Health Science Center Houston Texas

4. Department of Haematology, Institute of Clinical Medicine University of Oslo, Oslo University Hospital Oslo Norway

5. CHCMN Hemophilia and Thrombosis Center Children’s Hospital and Clinics of Minnesota Minneapolis Minnesota

6. Haemophiliezentrum, Klinik für Innere Medizin Vivantes Klinikum im Friedrichshain Berlin Germany

7. The National Hemophilia Center and Center of Thrombosis, Chaim Sheba Medical Center, Sackler School of Medicine Tel Aviv University Tel Aviv Israel

8. Hôpital Louis Pradel Université Claude Bernard Lyon France

9. Pathology, Microbiology and Immunology Vanderbilt University School of Medicine Nashville Tennessee

10. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Foundation Maggiore Hospital Policlinic Milan Italy

11. Department of Pediatrics, Nara Hemophilia Centre Nara Medical University Kashihara, Nara Japan

12. Novo Nordisk A/S Søborg Denmark

13. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City Iowa

Funder

Novo Nordisk

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13712

Reference22 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey

3. Guidelines for the management of hemophilia

4. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future;Jimenez‐Yuste V;Blood Transfus,2014

5. A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23

2. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

3. Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy;AboutOpen;2022-06-06

4. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective;Critical Reviews in Oncology/Hematology;2022-06

5. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia;Haemophilia;2022-03